This is a non-interventional study examining clinical trajectories and predictors of outcomes in the clinical high risk (CHR) population.
Clinical assessments will be collected monthly for the first year, and then at 18 and 24 months and at the point of conversion to psychosis.
The biomarker measures (imaging, EEG and event-related potentials, fluid-based biomarkers, cognitive assessments, and speech sampling) will be collected at baseline and at two months after study entry. Digital assessments (actigraphy as well phone app-based data collection) will be collected daily for the first year.
Cognitive assessments will be collected longitudinally at six, 12 and 24 months and at conversion to psychosis. Unbiased machine language and AI approaches will be used to derive algorithms that predict clinical outcomes: conversion to psychosis; persistent cognitive and functional impairment without psychosis; and remission of the CHR state.
As the Accelerating Medicines Partnership (AMP®) SCZ program Data Analytic Strategy Work Group is convened, there will be updates on the high-level strategy to identify ‘phenotypes’ or strata of CHR individuals based on multi-modal predictive algorithms.
Last Reviewed on July 28, 2022